<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00466284</url>
  </required_header>
  <id_info>
    <org_study_id>GGCP023/05-ML19497</org_study_id>
    <nct_id>NCT00466284</nct_id>
  </id_info>
  <brief_title>Phase II Trial of Tarceva in Patients With Non-Small Cell Lung Cancer</brief_title>
  <official_title>Phase II Trial of Tarceva Following Concurrent Chemo-Radiotherapy as First Line Therapy in Patients With Unresectable Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Gallego de Cancer de Pulmon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Gallego de Cancer de Pulmon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A open label non- randomized Phase II trial. It is anticipated that approximately 46 patients
      will be treated.

      STUDY OBJECTIVES

      Primary: Objective response rate

      Secondary: Progression free survival, Overall survival and Safety of Tarceva
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design: Phase II trial, open label, non-randomized and multicenter.

      Expected total enrollment: 46

      Study start: January, 2006

      Study completation: January, 2008
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2006</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Tarceva</measure>
  </secondary_outcome>
  <enrollment>46</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tarceva (erlotinib)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years.

          -  Patients must have histologically confirmed diagnosis of non-small cell lung cancer,
             which is not surgically resectable (stage IA- IIIB).

          -  Measurable disease.

          -  Written informed consent must be obtained prior to the inclusion into the trial.

          -  Karnofsky performance status of 80%.

          -  Patients must have been treated with no prior chemotherapy or radioterapy.

          -  Patients must have adequate bone marrow, liver and renal function.

               -  Bone Marrow: WBC &gt; 3000 x 103/mm3,

               -  Platelets &gt; 100 x 103/mm3,

               -  Hgb &gt; 10.0 gm/dl,

               -  ANC &gt;1500 x 103/mm3,

               -  Hepatic:Bilirubin &lt; 2 mg/dl (34 µmol/l); AST, ALT, and Alkaline Phosphatase &lt; 5 x
                  normal,

               -  Renal:Creatinine &lt; 1.5 mg/dl (132 µmol/l).

        Exclusion Criteria:

          -  Female patients who are pregnant or lactating.

          -  Patients who have used other investigational agents within 21 days prior to study
             entry.

          -  Patients who have received prior treatment with erlotinib or other anti-EGFR agent.

          -  Significant comorbidity.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joquin Casal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GGCP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joaquin Casal, MD</last_name>
    <phone>986811111</phone>
    <phone_ext>645</phone_ext>
    <email>joaquin.casal.rubio@sergas.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Grupo Gallego de Cancer de Pulmon</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruña</state>
        <zip>15701</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joaquin Casal, MD</last_name>
      <email>joaquin.casal.rubio@sergas.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2007</study_first_submitted>
  <study_first_submitted_qc>April 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2007</study_first_posted>
  <last_update_submitted>April 25, 2007</last_update_submitted>
  <last_update_submitted_qc>April 25, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

